Table 5 Prevalence of sarcopenia and sarcopenia categories according to FAS eGFR (ml/min/1.73m2) categories
|  | Non-sarcopenic (n = 1270) | Sarcopenic (n = 150) | p-value | ||
|---|---|---|---|---|---|
FAS eGFR category | No sarcopenia (n = 1114) | Probable sarcopenia (n = 156) | Confirmed sarcopenia (n = 65) | Severe sarcopenia (n = 85) | |
≥90 (n = 26) | 22 (84.6%) | 4 (15.4%) | 0.420 | ||
16 (61.5%) | 6 (23.1%) | 2 (7.7%) | 2 (7.7%) | Â | |
60–89 (n = 553) | 496 (89.7%) | 57 (10.3%) | 0.802 | ||
456 (82.5%) | 40 (7.2%) | 29 (5.2%) | 28 (5.1%) | Â | |
45–59 (n = 480) | 437 (91.0%) | 43 (9.0%) | 0.160 | ||
380 (79.2%) | 57 (11.9%) | 22 (4.6%) | 21 (4.4%) | Â | |
30–44 (n = 253) | 225 (89.0%) | 28 (11.1%) | 0.774 | ||
188 (74.3%) | 37 (14.6%) | 9 (3.6%) | 19 (7.5%) | Â | |
15–29 (n = 108) | 90 (83.3%) | 18 (16.7%) | 0.032 | ||
74 (68.5%) | 16 (14.8%) | 3 (2.8%) | 15 (13.9%) | Â | |
≥60 (n = 1059) | 955 (90.2%) | 104 (9.8%) | 0.119 | ||
852 (80.5%) | 103 (9.7%) | 53 (5.0%) | 51 (4.8%) | ||
< 60 (n = 361) | 315 (87.3%) | 46 (12.7%) | |||
262 (72.6%) | 53 (14.7%) | 12 (3.3%) | 34 (9.4%) | ||